vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.9M, roughly 1.7× Peraso Inc.). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -43.3%, a 17.8% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs -22.0%). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 1.0%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
NBY vs PRSO — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $2.9M |
| Net Profit | $-1.2M | $-1.2M |
| Gross Margin | 65.2% | 52.2% |
| Operating Margin | -37.2% | -44.6% |
| Net Margin | -25.5% | -43.3% |
| Revenue YoY | 126.1% | -22.0% |
| Net Profit YoY | 70.5% | 20.3% |
| EPS (diluted) | — | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $3.9M | ||
| Q4 24 | $4.8M | $3.7M | ||
| Q3 24 | $0 | $3.8M | ||
| Q2 24 | $2.4M | $4.2M | ||
| Q1 24 | $2.6M | $2.8M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-471.0K | ||
| Q4 24 | $-1.2M | $-1.6M | ||
| Q3 24 | $-1.2M | $-2.7M | ||
| Q2 24 | $-1.6M | $-4.4M | ||
| Q1 24 | $-3.2M | $-2.0M |
| Q4 25 | — | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | 65.2% | 56.3% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | 66.3% | 55.5% | ||
| Q1 24 | 68.2% | 46.4% |
| Q4 25 | — | -44.6% | ||
| Q3 25 | — | -36.8% | ||
| Q2 25 | — | -80.0% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | -37.2% | -44.3% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | -67.4% | -105.6% | ||
| Q1 24 | -87.1% | -128.9% |
| Q4 25 | — | -43.3% | ||
| Q3 25 | — | -37.4% | ||
| Q2 25 | — | -82.4% | ||
| Q1 25 | — | -12.2% | ||
| Q4 24 | -25.5% | -42.4% | ||
| Q3 24 | — | -70.6% | ||
| Q2 24 | -66.0% | -104.4% | ||
| Q1 24 | -122.2% | -72.1% |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-0.31 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | $-1.92 | $-0.98 | ||
| Q2 24 | $-1.37 | $-1.88 | ||
| Q1 24 | $-29.95 | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $4.6M |
| Total Assets | $3.4M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $430.0K | $3.3M | ||
| Q3 24 | $776.0K | $1.3M | ||
| Q2 24 | $751.0K | $1.9M | ||
| Q1 24 | $1.8M | $2.4M |
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $-129.0K | $3.5M | ||
| Q3 24 | $1.1M | $2.0M | ||
| Q2 24 | $-617.0K | $3.6M | ||
| Q1 24 | $160.0K | $6.7M |
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | — | $5.5M | ||
| Q1 25 | — | $6.7M | ||
| Q4 24 | $3.4M | $7.2M | ||
| Q3 24 | $3.9M | $7.2M | ||
| Q2 24 | $3.9M | $9.8M | ||
| Q1 24 | $5.4M | $11.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-1.1M |
| Free Cash FlowOCF − Capex | $-1.7M | — |
| FCF MarginFCF / Revenue | -35.4% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-966.0K | ||
| Q4 24 | $-1.7M | $-687.0K | ||
| Q3 24 | $-2.4M | $-683.0K | ||
| Q2 24 | $-1.4M | $-659.0K | ||
| Q1 24 | $-2.0M | $-2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
